retatrutide glucagon receptor Conceivable actions of in cardiomyocytes. Retatrutide / GLP-3: multi-receptor research

Acta Pharmacol Sin 36, 200208 (2015).

Retatrutide is an investigational injectable medication currently under clinical development for the management of obesity and type 2 diabetes

Because of these limitations, there was a desire for a GLP-1 agonist that could be taken orally at any time of the day without any food or water restrictions

Common side effects of semaglutide are usually mild and may include: Nausea Vomiting Diarrhea Constipation Abdominal pain Decreased appetite Indigestion The majority of side effects are transient and typically resolve spontaneously

Week 1-2 The typical dosing used in trials is 1 mg/week for the entirety, or 2 or 4 mg/week for 4 weeks and then staying on 4 mg/week for the rest of the trial, or titrating up to 8 or 12 mg/week

If symptoms are severe or accompanied by pain or vomiting, reach out to your healthcare team